Rudy Robert F, Du Rose
Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Handb Clin Neurol. 2017;143:309-316. doi: 10.1016/B978-0-444-63640-9.00031-X.
Cerebral cavernous malformations, vascular abnormalities comprised of endothelial cells in the absence of connective tissue or muscle, are often epileptogenic and often treated initially with antiepileptic drugs. This chapter discusses the role of pharmacotherapy in managing focal epilepsy secondary to cavernous malformations in adults, children, and pregnant women. Several drugs are available and potentially efficacious in suppressing seizures stemming from cavernous malformations. In addition, antiepileptic pharmacotherapy following surgical resection is indicated to decrease the risk of postoperative seizures. Finally, potential novel therapeutics targeting cavernous malformations are discussed.
脑海绵状血管畸形是由缺乏结缔组织或肌肉的内皮细胞组成的血管异常，通常具有致痫性，最初常采用抗癫痫药物治疗。本章讨论药物治疗在成人、儿童和孕妇脑海绵状血管畸形继发局灶性癫痫管理中的作用。有几种药物可用于抑制脑海绵状血管畸形引起的癫痫发作，且可能有效。此外，手术切除后进行抗癫痫药物治疗可降低术后癫痫发作的风险。最后，还讨论了针对脑海绵状血管畸形的潜在新型治疗方法。
